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Reply to Turnbull et al. and to Hulme et al.
From the Authors:
In a recent issue of the Journal, we reported a change in infection
prevalence observed over the 18 years of the AREST CF (Australian
Respiratory Early Surveillance Team for Cystic Fibrosis)
prospective study, speciﬁcally, a reduction in the prevalence of
bacterial infections (Pseudomonas aeruginosa, Staphylococcus
aureus, and Haemophilus inﬂuenzae), which resulted in Aspergillus
species becoming the most prevalent lower respiratory
infection cultured in recent years (1).
In a letter to the editor, Hulme and colleagues present
infection prevalence data from a 6-year BAL surveillance
program (SHIELD CF [The Study of Host Immunity and Early Lung
Disease in Cystic Fibrosis]) in preschool-aged children with cystic
ﬁbrosis (CF) conducted at three specialist CF centers in Ireland.
Differences in the prevalence of lower respiratory infections
between their cohort and our Australian cohort, as well as
possible explanations for these differences, are discussed in the letter.
The Irish data show a much higher prevalence of lower respiratory
S. aureus and H. inﬂuenzae infections and a much lower prevalence
of Aspergillus species infections. These differences are striking,
especially in the younger age group (0–2 yr).
Differences in the prevalence of bacterial infections between
CF centers are not surprising. Even within the AREST CF
cohort, signiﬁcant differences between the two participating
centers were reported (2). There could be numerous reasons
for such differences, including antibiotic stewardship, practices
involving antibiotic prophylaxis, varying protocols for the treat-
ment of pulmonary exacerbations and environmental factors (as
discussed by Hulme and colleagues), and patient adherence to
treatment, infection control, and airway clearance routines.
The decrease in the prevalence of S. aureus and
H. inﬂuenzae infections over the 18 years of the AREST
CF study coincided with an overall more aggressive treatment
approach. Speciﬁcally, use of chronic antibiotics increased
considerably. Between 2004 and 2018, the percentage of
preschool patients treated with long-term azithromycin and any
use of inhaled tobramycin increased from 0% to 30% and 4.7%
to 44%, respectively, possibly inﬂuencing the prevalence of
bacterial infections. Interestingly, prophylactic treatment with
amoxicillin–clavulanate did not change over the study period. In
their letter, Hulme and colleagues do not provide speciﬁc
information regarding antibiotic use in their patients, which
makes it difﬁcult to compare treatment effects on bacterial
infection prevalence between the cohorts.
In a different letter, Turnbull and colleagues raise concern
that infection prevalence in our study does not represent the
full picture of CF airway microbiology in preschool children
owing to a lack of report on samples obtained during
pulmonary exacerbations, such as oropharyngeal swabs and
induced sputum. We agree that it is possible that samples
obtained during exacerbations might have increased the incidence
of positive bacterial cultures. However, we aimed to report
lower airway infection prevalence. Including upper
airway samples, which have been shown to have a low
positive predictive value for detecting lower airway infection during
both exacerbations and clinical stability (3–5) (regardless of the
test’s sensitivity), would lead to an overestimation of the
prevalence of lower airway infection. Furthermore, including
samples obtained during exacerbations would introduce a
selection bias, which would also cause an overestimation of
infection. Thus, although we do agree that it is important to
understand exacerbation microbiology, it’s questionable
whether such data should be included in an epidemiological
study describing lower airway infection prevalence trends in
relatively well preschool children with CF. In addition, and
most importantly, exacerbation microbiology would not change
the signiﬁcant prevalence of lower respiratory Aspergillus
species infections reported in our study.
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The U.S. Cystic Fibrosis Foundation recently recognized
that “new and/or validated ways to better classify and
distinguish Aspergillus lung phenotypes” are an unmet
need in CF care, limiting diagnosis and treatment of
Aspergillus infections. As also presented in the letter
by Hulme and colleagues, the prevalence rates of Aspergillus
infections in patients with CF vary widely among studies,
mainly because of differences in the culturing methods
and sample-processing techniques used, but also because
of the different routines used for nebulized antibacterial
therapies (6). Furthermore, bacterial infections may
inhibit culture growth of Aspergillus species, which would
also inﬂuence the reported prevalence (6). Our cohort
showed an overall 40% incidence of Aspergillus species
infection in the ﬁrst 6 years of life, which is similar to what
has been reported in other studies (7–9).
Hulme and colleagues pose the question, “Which is the
greater evil, a higher prevalence of bacteria or a higher
prevalence of Aspergillus?” There is little doubt that lower
respiratory infections with bacteria cause lung damage.
However, despite current aggressive antibiotic treatment
regimens, preschool-aged children are still showing
signiﬁcant structural lung disease by 6 years of age (10). Thus,
it is essential to understand the implications of Aspergillus
infections, as they are not routinely treated. The use of
molecular techniques to better identify fungal infections
in patients with CF is critical for assessing the true
prevalence of Aspergillus species infections (6), and
programs like AREST CF and SHIELD CF provide
opportunities to further elucidate the clinical consequences of
Aspergillus infections in early CF lung disease. n
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